COMMUNIQUÉS West-GlobeNewswire

Evoke Pharma Requests Type A FDA Meeting to Plan for Resubmission of Gimoti™ NDA
27/06/2019
SOLANA BEACH, Calif., June 27, 2019 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused on treatments for gastrointestinal (GI) diseases, today announced that it has [...]
Hemostemix Announces Enrollment Update for the ACP-01 Phase II Critical Limb Ischemia Clinical Trial
27/06/2019
CALGARY, Alberta, June 27, 2019 (GLOBE NEWSWIRE) -- Hemostemix Inc. (“ Hemostemix ” or the “ Company ”) (TSX VENTURE: HEM; OTCQB: HMTXF) is pleased to announce that it has enrolled a total of forty (40) patients in its [...]
REPEAT - AgraFlora Organics Provides Licensing Guidance and Operational Updates at GMP-Certified GTA Bottling Facility
27/06/2019
VANCOUVER, British Columbia, June 27, 2019 (GLOBE NEWSWIRE) -- AgraFlora Organics International Inc. (“ AgraFlora ” or the “ Company ”) ( CSE: AGRA) (Frankfurt: PU31) (OTCPK: PUFXF ), a growth oriented and diversified [...]
Dova Pharmaceuticals Announces FDA Approval of Supplemental New Drug Application for DOPTELET® (avatrombopag) for Treatment of Chronic Immune Thrombocytopenia (ITP)
27/06/2019
Company Strengthens Thrombocytopenia Portfolio with ITP Approval and Expanded Partnership with Salix for Chronic Liver Disease (CLD) Indication Company to Host Conference Call at 9am EST DURHAM, N.C., June 27, 2019 ( [...]
ContraVir Pharmaceuticals Submits IND Application for CRV431 for NASH
27/06/2019
IND positions NASH as a second indication for CRV431, in addition to HBV EDISON, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV), a biopharmaceutical company focused on the [...]
SI-BONE’s iFuse Implant System Surpasses 40,000 Procedures
27/06/2019
Long-term prospective study with 5-year follow-up submitted for publication SANTA CLARA, Calif., June 27, 2019 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a Silicon Valley-based medical device company dedicated to [...]
Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer
27/06/2019
James Noble will transition to become a Non-Executive Director PHILADELPHIA and OXFORDSHIRE, United Kingdom, June 27, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP) today announced that Adrian [...]
SunGen Pharma Announces to Partner with Athenex Pharmaceutical to Launch Bivalirudin through PIV Challenges in US
27/06/2019
PRINCETON, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- SunGen Pharma, a privately held specialty pharmaceutical company which develops, contract manufactures, and sells pharmaceutical finished products, today announced to [...]
Ovid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome; Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020
27/06/2019
Phase 3 NEPTUNE Trial of OV101 Expected to Enroll the First Patients in the Third Quarter of 2019; CGI-I Angelman Syndrome Scale will be the Sole Primary Endpoint Ovid to Review NEPTUNE Trial Details and Additional [...]
Wave Life Sciences Announces Initiation of DYSTANCE 51, a Phase 2/3 Clinical Trial of Suvodirsen
27/06/2019
Global study designed to assess the efficacy and safety of suvodirsen in DMD patients amenable to exon 51 skipping Results intended to support regulatory approvals globally CAMBRIDGE, Mass., June 27, 2019 (GLOBE [...]
Entasis Therapeutics Announces New Results Supporting Advancement of Multiple Pathogen-Targeted Antimicrobial Programs at ASM Microbe 2019
27/06/2019
WALTHAM, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, [...]
Aucta Pharmaceuticals Announces Licensing of Lamotrigine New Drug Application
27/06/2019
PISCATAWAY, N.J., June 27, 2019 (GLOBE NEWSWIRE) -- Aucta Pharmaceuticals, Inc. ( Aucta ), a technology based company focusing on the development and commercialization of Branded Specialty Products, today announced that [...]
Zogenix Announces FDA Agreement to Proceed with Resubmission of FINTEPLA® NDA
27/06/2019
NDA resubmission, anticipated in third quarter 2019, can proceed without additional chronic toxicity studies EMERYVILLE, Calif., June 27, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical [...]
Todos Medical to Sponsor the Investacure ‘Cure Coin Awards Reception’ for Alzheimer’s and CTE Research at AAIC 2019 in Los Angeles
27/06/2019
REHOVOT, Israel, June 27, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer and [...]
CareDx Supports Momentum in Medicare Immunosuppressive Medication Legislation
27/06/2019
Kidney community rallies in support as introduction of the immunosuppression coverage bill is imminent BRISBANE, Calif., June 27, 2019 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA), a leading molecular diagnostics [...]
Apellis Pharmaceuticals Completes Enrollment of Phase 3 APL-2 (pegcetacoplan) Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with Eculizumab
27/06/2019
Top-line Data Anticipated in December 2019 CRESTWOOD, Ky. and WALTHAM Mass., June 27, 2019 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals Inc., (Nasdaq:APLS) a clinical-stage biopharmaceutical company focused on the [...]
Publishing of Orion Corporation's Half Year Report for January-June 2019 on 17 July 2019
27/06/2019
ORION CORPORATION PRESS RELEASE 27 JUNE 2019 at 14.30 EEST Publishing of Orion Corporation's Half Year Report for January-June 2019 on 17 July 2019 Orion will publish its Half Year Report for January-June 2019 on [...]
ProMIS Neurosciences’ PMN310 Shows Greater Therapeutic Potential vs. Other Amyloid-Beta-Directed Antibodies
27/06/2019
Data presented at Keystone Symposium on Neurodegenerative Diseases TORONTO, Ontario and CAMBRIDGE, Mass., June 27, 2019 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company [...]
OpGen’s Acuitas® AMR Gene Panel Shows Potential for Reducing Total Time to Targeted Therapy
27/06/2019
Collaborator data demonstrating OpGen’s rapid prediction of antibiotic resistance and detection of uropathogens presented at ASM Microbe 2019 GAITHERSBURG, Md., June 27, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc . (Nasdaq: [...]

Pages